1508 related articles for article (PubMed ID: 16960658)
1. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
2. Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry.
Feller N; Kuiper CM; Lankelma J; Ruhdal JK; Scheper RJ; Pinedo HM; Broxterman HJ
Br J Cancer; 1995 Sep; 72(3):543-9. PubMed ID: 7669559
[TBL] [Abstract][Full Text] [Related]
3. Multidrug resistance-related proteins in primary choroidal melanomas and in vitro cell lines.
van der Pol JP; Blom DJ; Flens MJ; Luyten GP; de Waard-Siebinga I; Koornneef L; Scheper RJ; Jager MJ
Invest Ophthalmol Vis Sci; 1997 Nov; 38(12):2523-30. PubMed ID: 9375571
[TBL] [Abstract][Full Text] [Related]
4. Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells.
Budworth J; Davies R; Malkhandi J; Gant TW; Ferry DR; Gescher A
Br J Cancer; 1996 May; 73(9):1063-8. PubMed ID: 8624264
[TBL] [Abstract][Full Text] [Related]
5. Kinetic analysis of calcein and calcein-acetoxymethylester efflux mediated by the multidrug resistance protein and P-glycoprotein.
Essodaigui M; Broxterman HJ; Garnier-Suillerot A
Biochemistry; 1998 Feb; 37(8):2243-50. PubMed ID: 9485370
[TBL] [Abstract][Full Text] [Related]
6. Foretinib, a c-MET receptor tyrosine kinase inhibitor, tackles multidrug resistance in cancer cells by inhibiting ABCB1 and ABCG2 transporters.
Nazari S; Mosaffa F; Poustforoosh A; Mortazavi M; Saso L; Firuzi O; Moosavi F
Toxicol Appl Pharmacol; 2024 Mar; 484():116866. PubMed ID: 38367674
[TBL] [Abstract][Full Text] [Related]
7. Porphyrin-lipid assemblies and nanovesicles overcome ABC transporter-mediated photodynamic therapy resistance in cancer cells.
Baglo Y; Liang BJ; Robey RW; Ambudkar SV; Gottesman MM; Huang HC
Cancer Lett; 2019 Aug; 457():110-118. PubMed ID: 31071369
[TBL] [Abstract][Full Text] [Related]
8. Probenecid reverses multidrug resistance in multidrug resistance-associated protein-overexpressing HL60/AR and H69/AR cells but not in P-glycoprotein-overexpressing HL60/Tax and P388/ADR cells.
Gollapudi S; Kim CH; Tran BN; Sangha S; Gupta S
Cancer Chemother Pharmacol; 1997; 40(2):150-8. PubMed ID: 9182837
[TBL] [Abstract][Full Text] [Related]
9. Non-P-glycoprotein drug export mechanisms of multidrug resistance.
List AF
Semin Hematol; 1997 Oct; 34(4 Suppl 5):20-4. PubMed ID: 9408957
[TBL] [Abstract][Full Text] [Related]
10. Overcoming Multidrug Resistance: Flavonoid and Terpenoid Nitrogen-Containing Derivatives as ABC Transporter Modulators.
M F Gonçalves B; S P Cardoso D; U Ferreira MJ
Molecules; 2020 Jul; 25(15):. PubMed ID: 32722234
[TBL] [Abstract][Full Text] [Related]
11. The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer.
Zhang L; Li Y; Wang Q; Chen Z; Li X; Wu Z; Hu C; Liao D; Zhang W; Chen ZS
Mol Cancer; 2020 Jan; 19(1):10. PubMed ID: 31952518
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Nanosystems on ATP-Binding Cassette Transporters: Understanding the Influence of Nanosystems on Multidrug Resistance Protein-1 and P-glycoprotein.
Mello FVC; de Moraes GN; Maia RC; Kyeremateng J; Iram SH; Santos-Oliveira R
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32290047
[TBL] [Abstract][Full Text] [Related]
13. MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport.
Zhang F; Throm SL; Murley LL; Miller LA; Steven Zatechka D; Kiplin Guy R; Kennedy R; Stewart CF
Biochem Pharmacol; 2011 Jul; 82(1):24-34. PubMed ID: 21459080
[TBL] [Abstract][Full Text] [Related]
14. Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression.
Lee JS; Scala S; Matsumoto Y; Dickstein B; Robey R; Zhan Z; Altenberg G; Bates SE
J Cell Biochem; 1997 Jun; 65(4):513-26. PubMed ID: 9178101
[TBL] [Abstract][Full Text] [Related]
15. Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein.
Draper MP; Martell RL; Levy SB
Br J Cancer; 1997; 75(6):810-5. PubMed ID: 9062400
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of the ABC transporter TAP in multidrug-resistant human cancer cell lines.
Izquierdo MA; Neefjes JJ; Mathari AE; Flens MJ; Scheffer GL; Scheper RJ
Br J Cancer; 1996 Dec; 74(12):1961-7. PubMed ID: 8980397
[TBL] [Abstract][Full Text] [Related]
17. The sulphonylurea glibenclamide inhibits multidrug resistance protein (MRP1) activity in human lung cancer cells.
Payen L; Delugin L; Courtois A; Trinquart Y; Guillouzo A; Fardel O
Br J Pharmacol; 2001 Feb; 132(3):778-84. PubMed ID: 11159731
[TBL] [Abstract][Full Text] [Related]
18. Multidrug resistance-modifying components in human plasma with potential clinical significance.
Mülder HS; Pinedo HM; Timmer AT; Rao BR; Lankelma J
J Exp Ther Oncol; 1996 Jan; 1(1):13-22. PubMed ID: 9414384
[TBL] [Abstract][Full Text] [Related]
19. Multidrug resistance-associated protein: a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion.
Barrand MA; Bagrij T; Neo SY
Gen Pharmacol; 1997 May; 28(5):639-45. PubMed ID: 9184795
[TBL] [Abstract][Full Text] [Related]
20. Development and characterisation of novel human multidrug resistant mammary carcinoma lines in vitro and in vivo.
Stein U; Walther W; Lemm M; Naundorf H; Fichtner I
Int J Cancer; 1997 Sep; 72(5):885-91. PubMed ID: 9311609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
